Terms: = Lymphoma AND ITK, PSCTK2, 3702, Q08881, ENSG00000113263, EMT, MGC126258, LYK, MGC126257 AND Treatment
91 results:
1. Epithelial-Mesenchymal Transformation Promotes the Progression of Hepatocellular Carcinoma through NF-κB/MMP9 Axis.
Li J; Cai Q; Wang Z; Wang L; Yang G; Zhang Z; Ge N; Hu S; Bai T
Discov Med; 2024 Apr; 36(183):666-677. PubMed ID: 38665016
[TBL] [Abstract] [Full Text] [Related]
2. EZH2 K63-polyubiquitination affecting migration in extranodal natural killer/T-cell lymphoma.
Li B; Zhou Q; Wan Q; Qiao X; Chen S; Zhou J; Wuxiao Z; Luo L; Ng SB; Li J; Chng WJ
Clin Epigenetics; 2023 Nov; 15(1):187. PubMed ID: 38031139
[TBL] [Abstract] [Full Text] [Related]
3. Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer.
Tanabe S; Boonstra E; Hong T; Quader S; Ono R; Cabral H; Aoyagi K; Yokozaki H; Perkins EJ; Sasaki H
Genes (Basel); 2023 Nov; 14(11):. PubMed ID: 38003016
[TBL] [Abstract] [Full Text] [Related]
4. ING1 inhibits Twist1 expression to block emt and is antagonized by the HDAC inhibitor vorinostat.
Yang Y; Ma B; Djamshidi M; Zhang Q; Sarkar A; Chanda A; Tran U; Soh J; Sandall C; Chen HM; MacDonald JA; Bonni S; Sensen CW; Zheng J; Riabowol K
Eur J Cell Biol; 2023 Sep; 102(3):151341. PubMed ID: 37459799
[TBL] [Abstract] [Full Text] [Related]
5. itk degradation to block T cell receptor signaling and overcome therapeutic resistance in T cell lymphomas.
Jiang B; Weinstock DM; Donovan KA; Sun HW; Wolfe A; Amaka S; Donaldson NL; Wu G; Jiang Y; Wilcox RA; Fischer ES; Gray NS; Wu W
Cell Chem Biol; 2023 Apr; 30(4):383-393.e6. PubMed ID: 37015223
[TBL] [Abstract] [Full Text] [Related]
6. [Astragali Radix-Curcumae Rhizoma combination inhibits proliferation, migration, and invasion of colon cancer HT-29 cells by regulating emt].
Yang Q; Sun Z; Zhu YM; Xiang DY; Zhang QY; Wang F; Yang G; Yang H; Tang DC; Wu XY
Zhongguo Zhong Yao Za Zhi; 2023 Feb; 48(3):736-743. PubMed ID: 36872237
[TBL] [Abstract] [Full Text] [Related]
7. Clinical summary of pediatric acute lymphoblastic leukemia patients complicated with asparaginase-associated pancreatitis in SCCLG-ALL-2016 protocol.
Wang J; Jia WG; Yang LH; Kuang WY; Huang LB; Chen HQ; Wang LN; Zhou DH; Liao N
Hematology; 2023 Dec; 28(1):2171723. PubMed ID: 36752506
[TBL] [Abstract] [Full Text] [Related]
8. Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms.
Jaeger A; Gambheer SMM; Sun X; Chernyakov D; Skorobohatko O; Mack T; Kissel S; Pfeifer D; Zeiser R; Fisch P; Andrieux G; Bräuer-Hartmann D; Bauer M; Schulze S; Follo M; Boerries M; von Bubnoff N; Miething C; Hidalgo JV; Klein C; Weber T; Wickenhauser C; Binder M; Dierks C
Blood; 2023 Jun; 141(23):2824-2840. PubMed ID: 36696631
[TBL] [Abstract] [Full Text] [Related]
9. miR-145-5p Targets Sp1 in Non-Small Cell Lung Cancer Cells and Links to BMI1 Induced Pemetrexed Resistance and Epithelial-Mesenchymal Transition.
Chang WW; Wang BY; Chen SH; Chien PJ; Sheu GT; Lin CH
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499676
[TBL] [Abstract] [Full Text] [Related]
10. DNA methylome and single-cell transcriptome analyses reveal CDA as a potential druggable target for ALK inhibitor-resistant lung cancer therapy.
Heo H; Kim JH; Lim HJ; Kim JH; Kim M; Koh J; Im JY; Kim BK; Won M; Park JH; Shin YJ; Yun MR; Cho BC; Kim YS; Kim SY; Kim M
Exp Mol Med; 2022 Aug; 54(8):1236-1249. PubMed ID: 35999456
[TBL] [Abstract] [Full Text] [Related]
11. Characterization of the impact of the
Abaji R; Roux V; Yssaad IR; Kalegari P; Gagné V; Gioia R; Ferbeyre G; Beauséjour C; Krajinovic M
Pharmacogenomics; 2022 May; 23(7):415-430. PubMed ID: 35485735
[No Abstract] [Full Text] [Related]
12. MCL-1 is a clinically targetable vulnerability in breast cancer.
Winder ML; Campbell KJ
Cell Cycle; 2022 Jul; 21(14):1439-1455. PubMed ID: 35349392
[TBL] [Abstract] [Full Text] [Related]
13. Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation.
Sala M; Allain N; Moreau M; Jabouille A; Henriet E; Abou-Hammoud A; Uguen A; Di-Tommaso S; Dourthe C; Raymond AA; Dupuy JW; Gerard E; Dugot-Senant N; Rousseau B; Merlio JP; Pham-Ledart A; Vergier B; Tartare-Deckert S; Moreau V; Saltel F
Oncogene; 2022 Apr; 41(18):2571-2586. PubMed ID: 35322197
[TBL] [Abstract] [Full Text] [Related]
14. LncRNA SNHG6 knockdown inhibits cisplatin resistance and progression of gastric cancer through miR-1297/BCL-2 axis.
Mei J; Liu G; Li R; Xiao P; Yang D; Bai H; Hao Y
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34821362
[TBL] [Abstract] [Full Text] [Related]
15. MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer.
Lee JL; Ekambaram P; Carleton NM; Hu D; Klei LR; Cai Z; Myers MI; Hubel NE; Covic L; Agnihotri S; Krappmann D; Bornancin F; Lee AV; Oesterreich S; McAllister-Lucas LM; Lucas PC
Mol Cancer Res; 2022 Mar; 20(3):373-386. PubMed ID: 34753803
[TBL] [Abstract] [Full Text] [Related]
16. Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.
Wang X; Fei Y; Liu X; Zhang T; Li W; Jia X; Liu X; Qiu L; Qian Z; Zhou S; Ren X; Zhai Q; Meng B; Li L; Zhang H
Aging (Albany NY); 2021 Sep; 13(17):21102-21121. PubMed ID: 34508613
[TBL] [Abstract] [Full Text] [Related]
17. Anticancer effect of myristicin on hepatic carcinoma and related molecular mechanism.
Bao H; Muge Q
Pharm Biol; 2021 Dec; 59(1):1126-1132. PubMed ID: 34410900
[TBL] [Abstract] [Full Text] [Related]
18. Targeting SUMOylation in cancer.
Du L; Liu W; Rosen ST
Curr Opin Oncol; 2021 Sep; 33(5):520-525. PubMed ID: 34280172
[TBL] [Abstract] [Full Text] [Related]
19. Isovitexin attenuates tumor growth in human colon cancer cells through the modulation of apoptosis and epithelial-mesenchymal transition via PI3K/Akt/mTOR signaling pathway.
Zhu H; Zhao N; Jiang M
Biochem Cell Biol; 2021 Dec; 99(6):741-749. PubMed ID: 34219464
[TBL] [Abstract] [Full Text] [Related]
20. Combination of Gemcitabine and Thymosin alpha 1 exhibit a better anti-tumor effect on nasal natural killer/T-cell lymphoma.
Chen M; Jiang Y; Cai X; Lu X; Chao H
Int Immunopharmacol; 2021 Sep; 98():107829. PubMed ID: 34119916
[TBL] [Abstract] [Full Text] [Related]
[Next]
